Exploring the Impact of Cognitive Profiles on the Response to Magnetic Seizure Therapy and Electroconvulsive Therapy

Why It Matters

These findings support using baseline cognitive assessments to personalize seizure‑therapy choices, potentially improving outcomes while minimizing cognitive side effects.

Key Takeaways

• MST matches ECT efficacy while preserving cognition.
• ECT benefits patients with higher baseline cognition in schizophrenia.
• ECT shows greater effect in depressed patients with poor cognition.
• Cognitive profiling predicts differential seizure‑therapy response.
• MST recovery times are significantly shorter than ECT.

Pulse Analysis

Electroconvulsive therapy has long been the gold standard for treatment‑resistant mood and psychotic disorders, yet its association with transient memory loss and executive dysfunction limits acceptance. Magnetic seizure therapy emerged as a technically distinct alternative that induces focal cortical seizures through high‑intensity magnetic fields, promising comparable antidepressant and antipsychotic effects with a reduced cognitive footprint. Recent meta‑analyses have hinted at MST’s advantage in language and autobiographical memory, but head‑to‑head data remain scarce, especially in heterogeneous populations such as schizophrenia and major depressive disorder. Understanding how patient characteristics intersect with these modalities is essential for evidence‑based decision making.

The multicenter trial led by Guo et al. enrolled 398 inpatients and applied latent profile analysis to uncover four baseline cognitive subtypes ranging from optimal to poor performance. While overall symptom reduction did not differ significantly between MST and ECT, the interaction between treatment and cognition was striking. In schizophrenia, patients with relatively intact cognition experienced the largest effect size with ECT, whereas in depression, those with severe cognitive deficits derived the greatest benefit from ECT. MST, by contrast, produced consistent improvements regardless of cognitive class and showed superior gains in processing speed and verbal learning, highlighting its potential as a universally tolerable option.

These results reinforce the growing paradigm of precision psychiatry, where neurocognitive profiling can guide the selection of seizure‑based interventions. Clinicians may prioritize MST for patients where cognitive preservation is paramount, while reserving ECT for cases where baseline cognition predicts a robust response. Future research should focus on longer follow‑up to assess durability of remission, integrate functional imaging to map MST‑induced network changes, and refine dosing algorithms to close the efficacy gap. As regulatory bodies consider MST’s wider adoption, the evidence base presented here offers a compelling argument for incorporating cognitive assessments into routine treatment algorithms for both MDD and SCZ.